The Globe and Mail reports in its Friday, March 1, edition that Raymond James analyst Rahul Sarugaser raised his recommendation for DRI Healthcare Trust to "strong buy" from "outperform" previously, touting the potential gains from growing demand for synthetic royalties. The Globe's David Leeder writes in the Eye On Equities column that Mr. Sarugaser gave his unit target a $2 boost to $24. Analysts on average target the units at $21.06. Mr. Sarugaser says in a note: "DRI Healthcare is seeing a significant upwell in demand for synthetic royalties among biopharma companies (de novo royalties created by the drug's marketer to fund operations vs. traditional royalties, which are held by inventors/academic institutions/small biotechs and monetized directly by royalty players like DRI). Management indicates that up to 50 per cent of its deal pipeline comprises synthetic royalties (up from less than 10 per cent), and DRI intends to allocate 20 to 40 per cent of assets toward these in them medium-term. ... Between outperformance in core royalty cash receipts and the trigger of three big sales milestones ($3.4-million from Orserdu I, $30.3-million from Orserdu II, $5.0-million from Vonjo II), DRI blew the doors off its 4Q23."